Nelson Advisors featured in ‘AI Companies Bet on Health Care to Rebuild Trust’ story

Nelson Advisors has been featured in the ‘AI Companies Bet on Health Care to Rebuild Trust’ story.

Source: https://ontimebrief.com/en/2026/08/31/ai-companies-bet-on-health-care-to-rebuild-trust/

The latest

Major AI companies are pushing deeper into health care and drug discovery as they seek new revenue and measurable social benefits that could counter anxiety over energy use, data centers and job losses. The strategy may intensify debate over the next two or three years about whether dedicating vast computing capacity to medical research justifies its costs. Even advanced models cannot yet deliver miracle treatments, while research tools may create serious security risks.

Details

Anthropic’s timeline: Anthropic is moving quickly in biology and medicine as it seeks to bolster investor confidence before its IPO. Chief executive Dario Amodei said the company hopes for “incredible results” in coming years and “early glimmers” in coming months. The expansion coincides with frontier labs facing enormous model-training and multi-gigawatt infrastructure costs.

Investment wave: Nvidia and Eli Lilly are building a $1 billion drug-discovery lab in San Francisco, pairing life-science researchers with AI model builders and engineers. Google spinoff Isomorphic Labs raised $2.1 billion to recruit AI and clinical talent and continues research collaborations with Novartis, Lilly and Johnson & Johnson.

Clinical trade-offs: AI is already accelerating drug development and helping clinicians interpret scans and diagnose conditions. Yet software and automated scribes can also increase health-care spending by documenting delivered care more thoroughly, complicating claims that wider adoption will necessarily reduce costs for patients or providers.

Biosecurity safeguards: AI-enabled research tools could be misused, including to make a biological weapon. Anthropic imposed strict safeguards on its next-generation Claude Fable 5 model after concluding that it could provide “significant uplift” to a malicious actor, placing safety questions alongside the promised research benefits.

Political pressure: U.S. communities have pursued data-center moratoriums and threatened lawsuits amid concern about resource use and employment. Companies also face strained relations with the Trump administration, which favors a hands-off regulatory approach while retaining safety and privacy oversight. Public distrust of major drugmakers creates another backlash risk if AI companies appear to prioritize profits over patients.

Between the lines

Lloyd Price, a partner at digital health M&A firm Nelson Advisors, described the life-sciences push as both revenue diversification and a “hearts-and-minds play.” He said genuine medical advances could recast AI from an environmental and security threat into an essential public utility, while stressing that drug discovery remains a team effort in which AI is only one participant.

What’s next

The next concrete indicator will be Anthropic’s promised “early glimmers” in biology and medicine over the coming months, followed by whether AI labs can link heavy computing investment to a measurable contribution or breakthrough in drug discovery as Anthropic and OpenAI prepare for public markets.